Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corp (NY: CVM )

2.440 -0.110 (-4.31%)
Official Closing Price Updated: 8:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,141
Open 2.560
Bid (Size) 2.360 (6)
Ask (Size) 2.650 (4)
Prev. Close 2.550
Today's Range 2.420 - 2.560
52wk Range 1.860 - 5.416
Shares Outstanding 44,714,679
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why CEL-SCI Shares Are Shooting Higher Today
CEL-SCI Corporation (NYSE: CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga

Performance

YTD
-1.21%
-1.21%
1 Month
-11.27%
-11.27%
3 Month
+3.39%
+3.39%
6 Month
+2.09%
+2.09%
1 Year
-31.65%
-31.65%

More News

Read More
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Why BlackBerry Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI's Lead Head & Neck Cancer Candidate Shows 43% Survival Extension
Via Benzinga
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
From CEL-SCI Corporation
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
From CEL-SCI Corporation
Via Business Wire
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
Via Benzinga
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
10-Year Phase 3 Trial Shows CEL-SCI's Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients
Via Benzinga
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Why Pinterest Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket
Via Benzinga
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
From CEL-SCI Corporation
Via Business Wire
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.